Pediatric Erythroid Sarcoma Diagnostically Confirmed by Identification of a Recurrent NFIA::CBFA2T3 Fusion

Obianuju Mercy Anelo,Jing Ma,Jennifer L. Neary,Selene C. Koo,Hiroto Inaba,Soniya N. Pinto,Nga Thi Nguyen,Thach Ngoc Hoang,Lan Ngoc Bui,Jeffery M. Klco,Gabriela Gheorghe,Patrick R. Blackburn
DOI: https://doi.org/10.1002/gcc.23251
2024-06-19
Genes Chromosomes and Cancer
Abstract:Erythroid sarcoma (ES) is exceedingly rare in the pediatric population with only a handful of reports of de novo cases, mostly occurring in the central nervous system (CNS) or orbit. It is clinically and pathologically challenging and can masquerade as a nonhematopoietic small round blue cell tumor. Clinical presentation of ES without bone marrow involvement makes diagnosis particularly difficult. We describe a 22‐month‐old female with ES who presented with a 2‐cm mass involving the left parotid region and CNS. The presence of crush/fixation artifact from the initial biopsy made definitive classification of this highly proliferative and malignant neoplasm challenging despite an extensive immunohistochemical workup. Molecular studies including RNA‐sequencing revealed a NFIA::CBFA2T3 fusion. This fusion has been identified in several cases of de novo acute erythroid leukemia (AEL) and gene expression analysis comparing this case to other AELs revealed a similar transcriptional profile. Given the diagnostically challenging nature of this tumor, clinical RNA‐sequencing was essential for establishing a diagnosis.
oncology,genetics & heredity
What problem does this paper attempt to address?